A federal court has issued a ruling in a case involving Glaxo Group Limited and GlaxoSmithKline Intellectual Property Development Limited against Transpire Bio Inc. The case centers on allegations of patent infringement related to a generic version of Glaxo's Breo Ellipta inhaler. The court's decision addresses a dispute over whether certain communications and documents should be protected from disclosure due to attorney-client privilege and work-product protections.
This ruling affects both parties involved in the case, particularly Transpire, which is seeking to market a generic inhaler. The outcome of this case could have significant implications for the pharmaceutical industry, especially regarding how companies handle communications with third-party consultants in the context of legal disputes.
Background
The plaintiffs in this case are Glaxo Group Limited and GlaxoSmithKline Intellectual Property Development Limited, collectively referred to as GSK. They allege that Transpire Bio Inc. is infringing on their patents by attempting to produce a generic version of their Breo Ellipta inhaler. GSK holds several patents related to this inhaler and claims that Transpire's actions violate these patents.
The dispute escalated to the court when Transpire filed a counterclaim seeking a declaratory judgment of noninfringement and invalidity of GSK's patents. The case was filed in the Southern District of Florida under docket number 0:25-cv-61939. The current motion for a protective order arose from Transpire's withholding of forty-six documents or communications, claiming they were protected by attorney-client privilege or work-product doctrine.
The Ruling
The court ruled on Transpire's motion for a protective order, granting it in part and denying it in part. The court determined that while some documents may be protected, Transpire did not provide sufficient information to justify a protective order for all the documents in question. The court stated, "Transpire has not provided the Court with a sufficient factual basis to conclude each communication should be protected."
Judge Melissa Damian referred the motion to a magistrate judge for appropriate disposition. The court ordered Transpire to produce an amended privilege log by October 16, 2026, that adequately explains the facts supporting the claims of privilege for each document. The court emphasized that the privilege log must provide specific details to determine if the privilege is properly claimed.
Impact
This ruling has significant implications for how companies in the pharmaceutical industry manage communications with third-party consultants during legal disputes. The court's decision highlights the importance of maintaining confidentiality and the potential for privilege claims to be challenged if not properly documented. The ruling also sets a precedent for how attorney-client privilege and work-product doctrine can apply to communications involving third-party consultants.
Going forward, companies may need to be more diligent in documenting their communications and ensuring that they can substantiate claims of privilege. This case could influence how similar disputes are handled in the future, particularly in the context of patent litigation and the pharmaceutical industry.
What's Next
Transpire is required to submit an amended privilege log by the specified deadline. If GSK believes that the documents still do not meet the requirements for protection after reviewing the amended log, they may challenge the claims again. The case may continue to evolve as both parties prepare for further legal proceedings.